1
Eaton Donald J, Tice Thomas R, Downie David B, Arensdorf Patrick A, Brenneman Rodney, Biggs Danielle L: Device and methods for treating paranasal sinus conditions. Sinexus, Eaton Donald J, Tice Thomas R, Downie David B, Arensdorf Patrick A, Brenneman Rodney, Biggs Danielle L, AMII Lisa A, October 12, 2006: WO/2006/107957 (111 worldwide citation)

Described here are paranasal sinus devices for treating paranasal sinus conditions. The devices include a cavity member, ostial member, and nasal portion. One or more of the cavity member, ostial member, and nasal portion may deliver an active agent for sustained release to treat the paranasal sinus ...


2
Tice Thomas R, Gilley Richard M: Drug delivery system and method of making the same.. Southern Res Inst, February 8, 1989: EP0302582-A1 (54 worldwide citation)

A compatible, biodegradable microcapsule delivery system for active ingredients, including hormonally active peptides, proteins, or other bioactive molecules, and a method of making the same. The ingredients are encapsulated in biodegradable copolymer excipients of varying mole ratios and the blend ...


3
Tice Thomas R, Pledger Kenneth L, Gilley Richard M: Encapsulated nucleic acids.. Southern Res Inst, December 9, 1987: EP0248531-A2 (50 worldwide citation)

RNA and/or DNA, e.g. poly(I:C) or anti-sense RNA, is encapsulated as microcapsules in a biodegradable, biocompatible polymeric material, for the controlled release of the nucleic acid on administration and the induction of interferon production.


4
Tice Thomas R, Staas Jay K, Gilley Richard M, Eldridge John H: Method and formulation for orally administering bioactive agents to and through the peyers patch.. Southern Res Inst, Univ Alabama, May 4, 1988: EP0266119-A2 (47 worldwide citation)

A method and formulation for orally administering a bioactive agent which comprises encapsulating the agent in one or more biodegradable and biocompatible polymer or copolymer excipients to form a microcapsule which is capable of passing through the gastrointestinal tract unaffected and being taken ...


5

6
Tice Thomas R, Lewis Danny H: Procede de microcapsulation. Stolle Res & Dev, April 9, 1982: FR2491351-A1 (26 worldwide citation)

PROCEDE D'OBTENTION DE MICROCAPSULES CHARGEES D'UN AGENT ACTIF.


7
Kent John S, Lewis Danny H, Sanders Lynda M, Tice Thomas R: Polypeptides microencapsules solubles a leau, Microencapsulation of water soluble polypeptides. Syntex, JOHNSON DOUGLAS S QC, October 23, 1984: CA1176565 (25 worldwide citation)

ABSTRACT OF THE DISCLOSURE This invention concerns novel sustained releasemicrocapsule compositions comprising water-soluble,hormonally active polypeptides and optionally, a polymerhydrolysis modifying agent encapsulated in bio-compatable, biodegradable polymers such aspoly(lactide-co-glycolide) cop ...


8
Tice Thomas R, Meyers William E: Encapsulated cells, their method of preparation and use.. Stolle Res & Dev, January 2, 1985: EP0129619-A1 (19 worldwide citation)

Compositions comprising living cells inside a capsule are prepared by encapsulation of the cells by a process which comprises: (a) dispersing living cells in an aqueous solution of a capsule wall-forming protein; (b) forming aqueous droplets of the cell containing dispersion in an aqueous-immiscible ...


9
Arensdorf Patrick A, Biggs Danielle L, Brenneman Rodney, Downie David B, Eaton Donald J, Tice Thomas R: Implantable sustained drug delivery device for releasing active agents to the osteomeatal complex. Sinexus, Arensdorf Patrick A, Biggs Danielle L, Brenneman Rodney, Downie David B, Eaton Donald J, Tice Thomas R, MAYER Mika, January 17, 2008: WO/2008/008389 (18 worldwide citation)

Described here are devices, methods, and kits for treating sinusitis and related respiratory conditions by locally delivering active agents to the osteomeatal complex over a sustained period of time. The devices may be passively fixed within the osteomeatal complex and/or include one or more feature ...


10
Kleinig Michael John, Tice Thomas R, Staas Jay K: Methods of inducing melanogenesis in a subject.. Clinuvel Pharmaceuticals, Kleinig Michael John, Tice Thomas R, Staas Jay K, SLATTERY John M, February 9, 2006: WO/2006/012667 (14 worldwide citation)

Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous de ...